The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Creative Commons License

Toy M., ÖNDER F. O., İDİLMAN R., Kabacam G., Richardus J. H., Bozdayi M., ...Daha Fazla

EUROPEAN JOURNAL OF HEALTH ECONOMICS, cilt.13, sa.5, ss.663-676, 2012 (SSCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 5
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s10198-012-0413-8
  • Dergi Adı: EUROPEAN JOURNAL OF HEALTH ECONOMICS
  • Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus
  • Sayfa Sayıları: ss.663-676
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness.